Literature DB >> 23743984

[Paradoxical skin reactions under therapy with TNF-alpha antagonists].

P Weisenseel1, K Reich.   

Abstract

Tumor necrosis factor α (TNF α) antagonists are an effective and established therapy option for chronic inflammatory diseases in rheumatology, gastroenterology and dermatology. However, some undesired but rare side effects of TNF α antagonists, so-called paradoxical skin reactions, have been observed. These are mostly in the form of psoriasiform skin alterations, including pustular variants, eczema, vasculitis and other rare skin diseases. This article provides an overview of the different variants of paradoxical skin reactions due to TNF α inhibitors and gives practical advice on the therapeutic consequences.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23743984     DOI: 10.1007/s00393-012-1127-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  15 in total

1.  Atypical psoriasis following rituximab for rheumatoid arthritis.

Authors:  Sarah A Hardcastle; Sam Gibbs; Lyn Williamson
Journal:  J Rheumatol       Date:  2012-06       Impact factor: 4.666

2.  Psoriasiform drug eruption due to abatacept.

Authors:  Kohei Kato; Takahiro Satoh; Aya Nishizawa; Hiroo Yokozeki
Journal:  Acta Derm Venereol       Date:  2011-05       Impact factor: 4.437

3.  Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series.

Authors:  Tina Bhutani; John Koo
Journal:  J Dermatolog Treat       Date:  2010-06-05       Impact factor: 3.359

4.  Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies.

Authors:  Alvaro C Laga; Ruth A Vleugels; Abrar A Qureshi; Elsa F Velazquez
Journal:  Am J Dermatopathol       Date:  2010-08       Impact factor: 1.533

5.  Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms.

Authors:  Mary E Sherlock; Thomas Walters; Merit M Tabbers; Karen Frost; Mary Zachos; Aleixo Muise; Elena Pope; Anne M Griffiths
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-05       Impact factor: 2.839

Review 6.  Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Authors:  Angelique N Collamer; Daniel F Battafarano
Journal:  Semin Arthritis Rheum       Date:  2010-06-26       Impact factor: 5.532

Review 7.  Innovative uses of tumor necrosis factor alpha inhibitors.

Authors:  Joni Mazza; Anthony Rossi; Jeffrey M Weinberg
Journal:  Dermatol Clin       Date:  2010-07       Impact factor: 3.478

Review 8.  Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Authors:  Uwe Wollina; Gesina Hansel; André Koch; Jaqueline Schönlebe; Erich Köstler; Gunter Haroske
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

Review 9.  Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.

Authors:  Justin M Ko; Alice B Gottlieb; Joseph F Kerbleski
Journal:  J Dermatolog Treat       Date:  2009       Impact factor: 3.359

10.  Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.

Authors:  Cornelia Tillack; Laura Maximiliane Ehmann; Matthias Friedrich; Rüdiger P Laubender; Pavol Papay; Harald Vogelsang; Johannes Stallhofer; Florian Beigel; Andrea Bedynek; Martin Wetzke; Harald Maier; Maria Koburger; Johanna Wagner; Jürgen Glas; Julia Diegelmann; Sarah Koglin; Yvonne Dombrowski; Jürgen Schauber; Andreas Wollenberg; Stephan Brand
Journal:  Gut       Date:  2013-03-06       Impact factor: 23.059

View more
  2 in total

Review 1.  [Pustular psoriasis].

Authors:  P Weisenseel; D Wilsmann-Theis; C Kahl; K Reich; R Mössner
Journal:  Hautarzt       Date:  2016-06       Impact factor: 0.751

2.  [Status quo and prospects for systemic therapy of atopic dermatitis. Biologics ante portas].

Authors:  T Biedermann; T Werfel
Journal:  Hautarzt       Date:  2015-02       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.